TCM
RDY icon

Tekla Capital Management’s Dr. Reddy's Laboratories RDY Stock Holding History

Tekla Capital Management’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-144,750
Closed -$1.17M – 201
2019
Q1 		$1.17M Sell
144,750
-37,750
-21% -$287K 0.05% 154
2018
Q4 		$1.38M Buy
+182,500
New +$1.28M 0.06% 145

Other funds holding RDY

Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $355M AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return

Tekla Capital Management's RDY Position: Q2 2019 in Review

Tekla Capital Management sold out of Dr. Reddy's Laboratories (RDY) in Q2 2019, closing a stake of 144,750 shares — an estimated $1.17M sold.

Tekla Capital Management first reported a position in RDY in Q4 2018 and held it in 2 quarters. The position peaked at $1.38M in Q4 2018. 150 funds tracked by Wall St. Rank hold RDY as of Q2 2019.

  • Tekla Capital Management reported no remaining Dr. Reddy's Laboratories position as of Q2 2019 after selling out during the quarter.
  • Tekla Capital Management sold 144,750 Dr. Reddy's Laboratories shares in Q2 2019, an estimated $1.17M.
  • Tekla Capital Management first reported a position in Dr. Reddy's Laboratories in Q4 2018 and held it in 2 quarters.
  • Tekla Capital Management's Dr. Reddy's Laboratories position peaked at $1.38M in Q4 2018.
  • 150 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2019.

Based on Tekla Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.